Geldanamycin is a benzoquinone ansamycin antibiotic which binds heat shock protein 90 (Hsp90) and its paralog GRP94, altering their actions.1,2,3 Through its interaction with these chaperones, geldanamycin indirectly affects numerous client proteins with roles in diverse cellular processes, including gene expression, cell proliferation, apoptosis, and angiogenesis. For example, geldanamycin inhibits c-jun expression in human colon adenocarcinoma HT29 cells (IC50 = 75 nM), inhibiting AP-1 binding.4 It also reduces signaling through mitogenic signaling proteins and interferes with steroid receptor function.1,5,6,7 Inhibitors of Hsp90, including geldanamycin, show promise in cancer therapy.8
1
Whitesell, L., Mimnaugh, E.G., De Costa, B., et al. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA918324-8328(1994).
2
Hadden, M.K., Lubbers, D.J., and Blagg, B.S.J. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem61173-1182(2006).
3
Chavany, C., Mimnaugh, E., Miller, P., et al. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem271(9)4974-4977(1996).
4
Vasilevskaya, I.A., and O'Dwyer, P.J. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res593935-3940(1999).
5
Stancato, L.F., Silverstein, A.M., Owens-Grillo, J.K., et al. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem272(7)4013-4020(1997).
6
Fukuyo, Y., Hunt, C.R., and Horikoshi, N. Geldanamycin and its anti-cancer activities. Cancer Lett29024-35(2010).
7
Smith, D.F., Whitesell, L., Nair, S.C., et al. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol15(12)6804-6812(1995).
8
Taldone, T., Sun, W., and Chiosis, G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem17(6)2225-2235(2009).
Whitesell, L., Mimnaugh, E.G., De Costa, B., et al. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA918324-8328(1994).
Vasilevskaya, I.A., and O'Dwyer, P.J. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res593935-3940(1999).
Stancato, L.F., Silverstein, A.M., Owens-Grillo, J.K., et al. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem272(7)4013-4020(1997).
Hadden, M.K., Lubbers, D.J., and Blagg, B.S.J. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem61173-1182(2006).
Chavany, C., Mimnaugh, E., Miller, P., et al. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem271(9)4974-4977(1996).
Fukuyo, Y., Hunt, C.R., and Horikoshi, N. Geldanamycin and its anti-cancer activities. Cancer Lett29024-35(2010).
Smith, D.F., Whitesell, L., Nair, S.C., et al. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol15(12)6804-6812(1995).
Taldone, T., Sun, W., and Chiosis, G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem17(6)2225-2235(2009).